Cannie Douglas Ewan, Akhtar Mohammed Majid, Elliott Perry
University College London Institute for Cardiovascular Science London, UK.
Barts Heart Centre, Barts Health NHS Trust London, UK.
Eur Cardiol. 2019 Jul 11;14(2):89-96. doi: 10.15420/ecr.2019.19.2. eCollection 2019 Jul.
Current diagnostic strategies fail to illuminate the presence of rare disease in the heart failure population. One-third of heart failure patients are categorised as suffering an idiopathic dilated cardiomyopathy, while others are labelled only as heart failure with preserved ejection fraction. Those affected frequently suffer from delays in diagnosis, which can have a significant impact on quality of life and prognosis. Traditional rhetoric argues that delineation of this patient population is superfluous to treatment, as elucidation of aetiology will not lead to a deviation from standard management protocols. This article emphasises the importance of identifying genetic, inflammatory and infiltrative causes of heart failure to enable patients to access tailored management strategies.
当前的诊断策略无法揭示心力衰竭人群中罕见疾病的存在。三分之一的心力衰竭患者被归类为患有特发性扩张型心肌病，而其他患者仅被标记为射血分数保留的心力衰竭。这些患者经常遭受诊断延误，这可能对生活质量和预后产生重大影响。传统观点认为，明确这一患者群体对治疗来说是多余的，因为病因的阐明不会导致偏离标准管理方案。本文强调识别心力衰竭的遗传、炎症和浸润性病因对于使患者能够获得量身定制的管理策略的重要性。
